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Chronic pelvic pain syndrome in men is characterized by lower urinary tract symptoms consisting of
pelvic pain, variable urinary symptoms, and sexual dysfunction. Chronic pelvic pain syndrome is
different from chronic prostatitis, in which an identiﬁable bacterial infection or a positive bacterial
culture can be obtained. Chronic pelvic pain syndrome affects approximately 7% of men and causes
signiﬁcant morbidity, disability, and cost. The assessment of men with chronic prostatitis/chronic pelvic
pain syndrome involves a cascade of diagnostic steps, including an evaluation of the clinical presentation,
physical examination, evaluation of urine and expressed prostatic secretions, special examination of the
seminal plasma, and a search for common bacteria and uncommon pathogens. Cystoscopy, urodynamics,
and medical imaging studies may provide valuable information for patients with predominantly urinary
symptoms. Histopathological examination of prostatic biopsy samples may also be beneﬁcial.
Copyright © 2014, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Themajority of symptomatic cases of chronic prostatitis (CP) are
classiﬁed as National Institutes of Health (NIH) category III or
chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Although the etiology of CP/CPPS is not well established, its clinical
presentation appears to result from the interplay between psy-
chological factors and dysfunction in the immune, neurological,
and endocrine systems. Recent studies have shown that increased
proinﬂammatory and decreased anti-inﬂammatory cytokines, an
autoimmune process, possible defects in the androgen receptors,
neurogenic inﬂammation, and central sensitization might be
involved in the pathogenesis of CP/CPPS. The prostate may not even
be the source of the symptoms. Finally, psychological stress may
produce measurable biochemical changes and inﬂuence other
processes [1].Buddhist Tzu Chi General
lien, Taiwan. Tel.: þ886 3
elief Tzu Chi Foundation. Publishe2. Deﬁnition of CP/CPPS
The NIH classiﬁcation of prostatitis syndromes [2] includes:
category I, acute bacterial prostatitis, which is associated with se-
vere prostatitis symptoms, systemic infection, and acute bacterial
urinary tract infection; category II, chronic bacterial prostatitis,
which is caused by chronic bacterial infection of the prostate with
or without prostatitis symptoms and usually with recurrent urinary
tract infections caused by the same bacterial strain; category III, CP/
CPPS, characterized by chronic pelvic pain symptoms and possibly
voiding symptoms in the absence of urinary tract infection; and
category IV, asymptomatic inﬂammatory prostatitis, in which
prostate inﬂammation exists in the absence of genitourinary tract
symptoms.3. Symptom scoring and questionnaires
The NIH Chronic Prostatitis Symptom Index (NIH-CPSI) is an
established international standard index for the evaluation of
symptoms of prostatitis, but not its diagnosis [2]. The validated
NIH-CPSI has been recommended to evaluate the severity of
symptoms [3] and to measure the outcome of a variety of thera-
peutic agents for CP/CPPS [4e13].d by Elsevier Taiwan LLC. All rights reserved.
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severity of symptoms relevant to chronic prostatitis. However, its
role as a diagnostic tool is debatable because not all of the ques-
tions/scores in the NIH-CPSI adequately distinguish between CP
and other urological disorders [14]. A 2-year prospective study of
symptoms was completed in menwith CP/CPPS enrolled in the NIH
Chronic Prostatitis Cohort study. The total scores on the NIH-CPSI of
293menwith complete data records showed a substantial variation
in symptoms. There was no evidence that the disorder worsened
signiﬁcantly during the 2-year follow up and about one-third of
men with long-standing symptoms demonstrated moderate to
marked improvement during this period [15].
A clinical phenotype system [urinary, psychosocial, organ-
speciﬁc, infection, neurological/systemic, and tenderness
(UPOINT)] was proposed to classify patients with urological pelvic
pain to help understand the etiology and to guide treatment [16].
The percentages of patients positive for each domain were 52%,
34%, 61%, 16%, 37%, and 53%, respectively. The number of positive
domains correlated with the severity of symptoms and a longer
duration of symptoms increased the number of positive domains.
Because each domain has speciﬁc targeted treatments, it was pro-
posed that multimodal treatment might be guided best by the
UPOINT phenotype.
One study looked at 100 patients undergoing multimodal
treatment based on the UPOINT phenotype and measured the
response at least 6 months after treatment. The results showed that
multimodal treatment using UPOINT led to a signiﬁcant improve-
ment in symptoms and quality of life [17]. A recent study evaluated
the presence and importance of pain catastrophizing among men
diagnosed with CP/CPPS. A total of 61men completed the NIH-CPSI,
Short-Form McGill Pain Questionnaire, and Coping Strategies
Questionnaire to evaluate pain catastrophizing; the International
Index of Erectile Function was also scored according to the UPOINT
system. The results showed that the patients with a high tendency
for catastrophizing (Coping Strategies Questionnaire score 20)
had higher UPOINT and pain scores and also a worse quality of life
and quality of life impact [18].
There was a remarkable correlation between season and pain
intensity. Pain was considered to be three times more intense
during the winter months. This result conﬁrms the association
between cold and symptom intensity in the Scandinavian coun-
tries, where the seasonal temperature variation spans a wide range
and winters are long [19].
In one study, there was a high degree of overlap of storage
symptoms, voiding symptoms, and pain symptoms in patients who
reported urological symptoms, with few observed differences be-
tween sexes. Thirty-four percent of the men and 43% of the women
with storage or voiding symptoms also had pain symptoms. Ninety
percent of men and 94% of women with pain also had voiding or
storage symptoms [20]. A symptom-based classiﬁcation system
may identify and address all patients' complaints more accurately.
Overlapping patterns of lower urinary tract symptoms and pelvic
pain were also commonly found in a racially and ethnically
diverse community-based population. Overall, approximately 16%
of men and women had one symptom pattern, whereas 7% had
overlap patterns. Except for urinary incontinence and interstitial
cystitis/painful bladder syndrome in both men and women, the
prevalence of all symptom complexes related to benign prostatic
hyperplasia and CP/CPPS were signiﬁcantly associated with one
another [21].
In summary, the NIH-CPSI is becoming established as an in-
ternational standard for symptom evaluation in prostatitis, but
not for diagnosis. The NIH-CPSI total score has a high internal
consistency in the evaluation of the severity of current symptoms
and in measuring outcomes, i.e., the longitudinal course ofsymptoms with time and/or treatment. A clinical phenotype
system, UPOINT, has been proposed to classify patients with CP/
CPPS and the score is associated with symptom severity. Multi-
modal treatment might be guided best by the UPOINT
phenotype.
4. Sexual and ejaculatory dysfunction in CP/CPPS
The sexual function of 1274 European men with lower urinary
tract symptoms was assessed by the Danish Prostate Symptom
Score Sex Questionnaire. Erectile dysfunction and reduced ejacu-
lation were highly prevalent in men with lower urinary tract
symptoms and were strongly related to increasing age and lower
urinary tract symptom severity [22]. Another study investigated
ejaculatory pain in a cohort with CPPS to evaluate associations with
symptoms, quality of life, and risk factors. They found that patients
with CPPS and persistent ejaculatory pain had more severe symp-
toms that were less likely to improve with time than other patients
with CPPS [23].
Sexual dysfunction, premature ejaculation, decreased libido,
and erectile dysfunction are considered to be common in patients
with CP/CPPS. Data from the Giessen cohort study showed that 42%
of patients with CP/CPPS reported erectile dysfunction and 26%
reported premature ejaculation. Furthermore, these disorders lead
to reduced frequency of sexual contact [3].
One study evaluated CP/CPPS by correlating the six-domain
UPOINT phenotype system with clinically relevant parameters.
The number of positive domains and the NIH-CPSI and its quality of
life section were linked; however, there was no correlation be-
tween the number of positive domains and the International Index
of Erectile Function-5 ejaculatory pain, painful micturition, cold
sensitivity, or pain localization, except for scrotal pain. Therewas an
obvious link between catastrophizing and the NIH-CPSI [24]. One
European study investigated the addition of a sexual dysfunction
domain in regard to symptom correlation and the internal consis-
tency of the system. The consistency of the UPOINT CP/CPPS clinical
phenotyping system was generally conﬁrmed by the study and
further reﬁned by adding a sexual dysfunction domain [25]. How-
ever, another study found that the inclusion of an erectile domain
to the UPOINT phenotype did not improve correlation with symp-
tom severity in men with CP/CPPS [26].
CPPS is known to have a negative impact on quality of life,
especially on intimate relationships and sexual function. In a
Malaysia study, 72.3% of men with CP/CPPS reported sexual
dysfunction [27]. Patients with CPPS differed from controls by
reporting signiﬁcantly fewer sexual desires or thoughts, fewer
sexual activities, less arousal/erectile function, less orgasm func-
tion, and more genital pain during or after intercourse [28]. This
study suggested that interventions addressing psychological factors
affecting sexual responses should be further studied in evaluation
and treatment to improve sexual function and satisfaction in men
with CPPS.
In summary, CP/CPPS has a negative impact on sexual function
and on quality of life. The evaluation of patients with CP/CPPS
should include assessment of erectile dysfunction and ejaculation
pain. Inclusion of an erectile domain to the UPOINT phenotype does
not conclusively improve correlation with symptom severity in
men with CP/CPPS.
5. Somatization disorders, psychological impact, and quality
of life in patients with CP/CPPS
Psychosomatic factors are often neglected in the evaluation of
CP/CPPS in urological practice. Diagnostic and therapeutic strate-
gies should address the involvement of somatic and psychogenic
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such as somatization, depression, anxiety, hypochondriasis, and
weak masculine identity play an important role in questionnaire-
based studies [28].
Somatization disorder has been described in several comorbid
functional syndromes of urological CPPS, such as irritable bowel
syndrome. Female patients with urological CPPS were more likely
to endorse a polysymptomatic, polysyndromic symptom pattern
than female controls. By contrast, male patients did not report more
extra-pelvic pain than male controls [29].
Anxiety and depression are the two most prevalent clinical
manifestations of patients with CP/CPPS and have adverse effects
on the health of the patients and the prognosis of comorbidities.
One preliminary study from China reported that male patients with
CP/CPPS had a higher prevalence of psychological disorders than
controls. Of the 77 patients studied, 48 (62.3%), ﬁve (6.5%), and one
(1.2%) had anxiety, depression, or both, respectively. The prevalence
of anxiety and depression and the symptom scores on the Hospital
Anxiety and Depression Scale were both higher for younger (<35
years) than older (>35 years) age groups [30].
A population-based study aimed to prospectively examine the
relationship between a history of CP/CPPS and the risk of devel-
oping depressive disorder in Taiwan. Of a total of 18,306 patients,
163 (5.34%) from the CP/CPPS group and 494 (3.24%) from the
comparison group had a subsequent diagnosis of depressive dis-
order during the 3-year follow-up period, suggesting that patients
with CP/CPPS have a higher risk of depressive disorder than pa-
tients without CP/CPPS [31]. A study of 152 patients with CPPS and
204 patients with irritable bowel syndrome showed that 111
(31.2%) patients had both disorders. The patients with both CPPS
and irritable bowel syndrome had total NIH-CPSI and pain subscale
scores that were signiﬁcantly higher than patients with CPPS
alone [32].
Tripp et al [33] found that depressive symptoms and pain in-
tensity signiﬁcantly predicted poor quality of life in a study of 463
menwith CP/CPPS. They concluded that CP/CPPS is associated with
negative psychological factors and reduced quality of life; pain in-
tensity was the most robust predictor of a poorer quality of life. The
ﬁnding was also supported by a Korean study [34] and a
population-based cross-sectional survey of Finnish men [35].
Patients with CPPS had consistently higher scores for hypo-
chondriasis, depression, and hysteria than controls on the Minne-
sota Multiphasic Personality Inventory and on a somatization and
depression scale [36]. These results indicate that depression and
psychosocial distress are common among patients with CP, which
indicates a need for careful evaluation and attention to psycho-
logical symptoms.
CP/CPPS-like symptoms were common and had an important
impact on quality of life in a study in a large healthy population. Of
all NIH-CPSI symptoms, urinary frequency was associated with the
least favorable quality of life, followed by incomplete bladder
emptying, pain frequency, and pain intensity. It was concluded
that these symptoms should represent the main therapeutic tar-
gets in affected patients [37]. Another study followed up the
symptoms and quality of life of men with CP/CPPS for 2 years.
Interestingly, there was no evidence that the disorders worsened
signiﬁcantly and one-third of men with long-standing symptoms
demonstrated moderate to marked improvement during this
period [15].
In summary, patients with CP/CPPS have a high prevalence of
psychological disorders such as depression, anxiety, and hypo-
chondriasis. Diagnostic and therapeutic strategies should address
the involvement of somatic and psychogenic factors in the patho-
genesis of CP/CPPS. Careful evaluation and attention to psycho-
logical symptoms are helpful in the treatment of CP/CPPS.6. Physical examination
6.1. Myofascial trigger points and musculoskeletal dysfunction
Myofascial pain is a possible etiology for category III CP/CPPS,
either secondary to infection/inﬂammation or as the primary cause.
Pathological tenderness of the striated muscle was observed in
88.3% of men with CP/CPPS [38]. This myofascial tenderness was
always associated with an inability to relax the pelvic ﬂoor efﬁ-
ciently with a single or repetitive effort. A hypertonic urethral
sphincter was noted during urodynamic studies.
A controlled study of menwith CPPS categories IIIA and IIIB and
healthy controls showed that patients with CPPS had signiﬁcantly
greater pain and tension on palpation of the psoasmuscle and groin
than healthy mean without pelvic pain [39]. Signiﬁcant improve-
ment was found after a 12-week biofeedback pelvic ﬂoor re-
education and bladder training program [40]. A study using the
Manual Tender Point Survey to assess 62 men with CP/CPPS cate-
gories IIIA and IIIB and 98 men without pelvic pain revealed that
men with CP/CPPS had more tenderness than men without CPPS.
Tenderness in men with CPPS was distributed throughout the
pelvis and was not speciﬁc to the prostate [41].
A combination of manual physiotherapy and speciﬁc relaxation
training is effective in treating patients with CP/CPPS. In a study of
72 men who underwent treatment with physiotherapy and relax-
ation training, the pain sites were the penis in 90.3% of men, the
perineum in 77.8%, and the rectum in 70.8%. Puborectalis/pubo-
coccygeus and rectus abdominis trigger points reproduced penile
pain, whereas external oblique muscle palpation elicited supra-
pubic, testicular, and groin pain in most of the patients [42]. It was
suggested that identifying the site of clusters of trigger points in-
side and outside the pelvic ﬂoor may provide focused therapeutic
approaches.
New clinical phenotyping demonstrates that pelvic tenderness
is an important component of urological CPPS. In one recent study,
pressure pain thresholds on ten genito-pelvic sites and one control
site (deltoid) were measured using a digital algometer. Men with
CPPS had reliably lower pain thresholds than controls in all loca-
tions, including the deltoid. Men with CPPS also demonstrated
consistently lower overall pain thresholds regardless of location.
Furthermore, pressure pain thresholds were able to correctly
distinguish patients from controls 77% of the time. Pressure pain
thresholds appear to be a promising method of assessing tender-
ness in men with CPPS [43].
6.2. Digital rectal examination and abdominal examination
We could not ﬁnd a systemic review, randomized controlled
trial, or clinical trial which contributed to the evaluation of digital
rectal examinations or abdominal examinations of patients with
CPSS. In a data review, 51% of the 384menwith CPPS, but only 7% of
the 121 asymptomatic controls, had any tenderness. In patients
with CPSS, the most common pain site was the prostate (41%),
followed by the external and internal pelvic ﬂoor (13% and 14%,
respectively), and the suprapubic area (9%). Extra-prostatic
tenderness may identify a cohort of patients with a neuromus-
cular source of pain [44]. A digital rectal examination is helpful in
the differential diagnosis of bacterial prostatitis. Patients with CP/
CPPS may perceive pressure pain rather than tenderness on digital
rectal examination of the prostate.
In summary, examination of the abdomen, external genitalia,
perineum, and prostate is mandatory. New clinical phenotyping
demonstrates that pelvic tenderness is an important component of
urological CPPS. Tenderness in men with CPPS is distributed
throughout the pelvis and is not speciﬁc to the prostate. Identifying
J.-L. Chen et al. / Tzu Chi Medical Journal 26 (2014) 151e156154the site of clusters of trigger points inside and outside the pelvic
ﬂoor may provide focused therapeutic approaches.
7. Cystoscopy
Bladder neck hypertrophy was found in 60% of men with CPPS
category IIIB in a prospective study [45]. The urodynamic ﬁndings
of increased detrusor pressure, decreased maximum ﬂow-rate, and
increased post-void residual urine implied that the cystoscopic
ﬁndings were compatible with bladder neck dysfunction. There
could be an overlap between CPPS and male lower urinary tract
dysfunction due to bladder neck or urethral dysfunction. Cystos-
copy was not recommended as a routine procedure except for pa-
tients with obstructed voiding symptoms or hematuria, or other
suspected lower urinary tract pathology [46].
8. Imaging methods for evaluation
8.1. Transrectal ultrasound of the prostate and pelvic ﬂoor
Transrectal ultrasonography of the prostate (TRUS-P) is
frequently used to determine the prostatic volume and transition
zone index, and in detecting prostatic cancer. However, the role of
TRUS-P in CP/CPPS remains debatable and ultrasound features
alone cannot be used for the ﬁnal diagnosis. Color Doppler ultra-
sound may be of some assistance.
Color Doppler TRUS-P was used to evaluate 25 patients with
acute prostatic syndrome, seven patients with asymptomatic CP, 13
patients with prostate cancer, and six healthy controls. Marked
color increases indicative of acute inﬂammation were observed in
all men with acute prostatic syndrome and the color intensity
matched the severity of acute prostatic syndrome symptoms [47].
Another study evaluated the presence of abnormal blood ﬂow in
patients with CP/CPPS using color Doppler TRUS-P. Signiﬁcant in-
creases in blood ﬂow in the prostatic capsule and diffuse ﬂow
throughout the prostatic parenchyma were observed [48].
Transrectal ultrasound was used to measure certain parameters
in 37 patients with CP/CPPS and 23 healthy volunteers. On multi-
variate analysis, a hypoechoic periurethral zone volume was an
independent predictive factor for worse NIH-CPSI pain, urinary
scores, and total scores. Posterior prostate lip thickness was the
only factor predictive of a worse International Prostate Symptom
Score in patients with CP/CPPS. Measurement of the hypoechoic
periurethral zone volume, posterior prostate lip thickness, and
bladder neck thickness could be useful in following up patients
with CP/CPPS [49].
Prostatic calciﬁcation is common in asymptomatic elderly men.
However, young men with CPPS often have signiﬁcantly calciﬁed
prostates. Among 47 menwith CPPS who underwent TRUS-P, those
with prostatic calciﬁcation were less likely to have pelvic ﬂoor
tenderness, but were more likely to have bacteria in the prostatic
ﬂuid and a higher median white blood cell count. Prostatic calciﬁ-
cation was common in patients with CPPS and was associated with
greater inﬂammation, bacterial colonization, and symptom dura-
tion [50]. However, another study revealed that prostatic calculi
were not an independent predictive factor of severe lower urinary
tract symptoms. Men with prostatic calculi had more severe lower
urinary tract symptoms not only because of prostatic calculi, but
also because of age and a large prostatic volume [51].
Ultrasonography of the pelvic ﬂoor muscle was used to measure
the anorectal angle and levator plate angle in men with urological
CPPS. The ultrasound probe was placed on the perineum and three-
dimensional images were taken at rest and during contraction of
the pelvic ﬂoor muscle. Men with CPPS had more acute anorectal
angles than controls, both at rest and during contraction. MenwithCPPS had signiﬁcantly more acute levator plate angles during
contraction and levator plate excursion. Acute anorectal angles
were positively correlated with greater pain and sexual dysfunc-
tion. Anxiety was correlated with more acute anorectal angles and
more obtuse levator plate angles [52].
8.2. Magnetic resonance imaging
Magnetic resonance imaging was found to be insensitive in
differentiating prostate cancer from other prostatic disorders. In a
group of patients with prostatic cancer, benign prostatic hyper-
plasia, acute bacterial prostatitis, chronic bacterial prostatitis,
CPPS, and in symptom-free controls, the accuracy in the diagnosis
of prostate cancer was 74% (sensitivity 53% and speciﬁcity 83%);
the positive and negative predictive values were 53% and 82%,
respectively. The accuracy of the diagnosis of cancer was high, but
the differentiation of bacterial prostatitis from cancer was difﬁ-
cult [53].
Combined magnetic resonance imaging and three-dimensional
magnetic resonance spectroscopic imaging data were examined
retrospectively in 12 patients with radical prostatectomy speci-
mens that contained regions of CP larger than 6 mm in the pe-
ripheral zone. With magnetic resonance spectroscopic imaging,
pathologically conﬁrmed CP may demonstrate a metabolic abnor-
mality that leads to a false-positive diagnosis of cancer. The most
commonmagnetic resonance imaging ﬁnding in CP was a focal low
signal intensity that was not speciﬁc for cancer [54].
9. Urodynamic study and physiological testing
Patients with CP/CPPS may have both storage and voiding
symptoms. Bladder outlet obstruction or detrusor over-activity
should ﬁrst be excluded in patients with lower urinary tract
symptoms. One previous study revealed that only 1.6% of patients
with CP had bladder outlet obstruction [55]. Although patients with
chronic bacterial prostatitis (category II) had signiﬁcantly lower
ﬂow-rates than the controls in one study, the parameters for
chronic bacterial prostatitis and CP/CPPS were similar [56]. Uro-
dynamics evaluation showed that men with CP/CPPS and voiding
difﬁculty had a low maximum ﬂow-rate and increased intravesical
pressure and, in some patients, increasing urethral pressure. The
study concluded there might be dysfunctional voiding in patients
with CP/CPPS and lower urinary tract symptoms [57]. Another
study showed obstructive urodynamics ﬁndings in 60% of patients
with CP/CPPS, implying an overlap between CPPS and male lower
urinary tract dysfunction due to bladder neck or urethral
dysfunction [45].
In neurophysiological testing, men with CPPS were found to
have signiﬁcantly higher pain intensity at lower temperatures and
higher peak computer-generated visual analog pain scores than
controls. This suggested that neural mechanisms involving sensi-
tization are involved in the pathophysiology of CPPS [58]. A study
attempting to deﬁne CPPS by quantitatively assessing thermal
sensory function revealed that men with CPPS had altered heat
sensation/pain sensitization (higher mean peak computerized vi-
sual analog scale values) in the perineum compared with controls
[59]. Interestingly, 83% of men with CP/CPPS reported that cold
temperatures aggravated symptoms and/or induced a relapse.
Sixty-three percent of patients stated that taking a hot bath and
46% reported that spending time in a hot climate decreased
symptoms [60].
Patients with CP/CPPS might have histological and physiological
bladder changes similar to those documented in patients with
painful bladder syndrome/interstitial cystitis. Thirty-ﬁve patients
with CP/CPPS according to the clinical criteria of the NIH were
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Pelvic painwas reported in all patients. A potassium sensitivity test
was positive in 26 (84%) of the 31 patients who presented with
urinary symptoms in the ﬁlling phase. Glomerulations were
observed on bladder cystoscopy in 24 (68.6%) patients [61]. It was
concluded that the symptoms in some patients diagnosed with CP/
CPPS might be related to bladder dysfunction rather than prostatic
inﬂammation.
Potassium chloride (KCl) instillation is known to cause pain in
most patients with painful bladder syndrome/interstitial cystitis or
CP/CPPS, reﬂecting urinary epithelial dysfunction. A positive KCl
test was found in 84% of men with CP/CPSS, which was almost
identical to the rate reported for men with painful bladder syn-
drome/interstitial cystitis (79%) [62]. However, another study found
that the rates of positive KCl test were 50% and 36.5% in the CP/CPPS
and control groups, respectively (p ¼ 0.160). There was no signiﬁ-
cant correlation of KCl sensitivity scores with NIH symptom scores
[63]. The role of the KCl test in the differential diagnosis of CP/CPPS
remains inconclusive.
Capsaicin (5 mL at a concentration of 1 mM) in a diagnostic test,
as well as a potential therapeutic tool, was applied topically to the
skin of the perineal body of menwith CP/CPPS and healthy controls.
The patients were asked to mark the intensity of any heat or
burning sensation on a visual analog scale. The patients with CP/
CPPS reported a heat/burning sensation intensity that was statis-
tically greater than that reported by the healthy controls (7.5 vs. 4.3,
p < 0.001) and a shorter time to heat sensation onset andmaximum
intensity. Sixteen of the 22 patients reported an improvement in
symptoms after 7 days of capsaicin treatment and the mean NIH-
CPSI score decreased [64]. The testing was similar to the sensiti-
zation test of C-ﬁbers and the therapeutic effect was similar to that
of central desensitization.
In summary, in selected patients with obstructive voiding
symptoms, it is reasonable to consider urodynamic evaluation to
check for bladder neck or urethral dysfunction. A KCl sensitivity test
to elicit urothelial dysfunction in CP/CPPS is optional. A thermal
sensory test may have potential in the evaluation of CP/CPPS.
10. Histological study of CP/CPPS
A prospective study examined prostate histopathology in 368
biopsy samples from 97 patients with symptoms of CP/CPPS to
systematically characterize inﬂammation. The degree of prostatic
inﬂammation was minimal/absent in 95% of patients; 4% had
moderate and 1% had severe inﬂammation [65]. Another systematic
literature review of papers from 1979 to 1999 concluded that
prostatic inﬂammation is a common histopathological observation,
although its association with CP/CPPS has not yet been completely
deﬁned [66].
In the REDUCE trial to determine if daily doses of dutasteride
(0.5 mg) reduces the risk of biopsy-detectable prostate cancer,
there was evidence of a relationship between the degree of lower
urinary tract symptoms and the degree of chronic inﬂammation.
Both age and average chronic inﬂammation were signiﬁcant in
linear regression after adjustment for other covariates; for both
variables, more severe inﬂammation was associated with higher
International Prostate Symptom scores [67].
One recent study evaluated the signiﬁcance of histological
prostatitis in patients with benign prostatic hyperplasia and acute
urinary retention and those with prostatic adenocarcinoma. His-
tological prostatitis was almost twice as common in patients with
urinary retention associated with underlying benign prostatic hy-
perplasia than in patients with prostatic adenocarcinoma, but there
was no signiﬁcant difference in the duration of catheterization,
prostatic volume, or presence of urinary tract infection, suggestingthat histological prostatitis more often contributes to the devel-
opment of retention in patients with underlying benign prostatic
hyperplasia than in those with prostatic adenocarcinoma [68].
In summary, the histological study of prostatic tissue is helpful
in the diagnosis of adenocarcinoma, but not CP/CPPS. Most chronic
inﬂammation in CP/CPPS is mild. Prostate biopsy samples in pa-
tients with CPPS may be of more beneﬁt in research than in clinical
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